Methotrexate Interactions: Drugs, Alcohol, and Supplements

Methotrexate interacts with a surprisingly long list of common drugs, supplements, and everyday substances, partly because it depends heavily on the kidneys for clearance and partly because it works by disrupting folate metabolism. Anything that slows its exit from the body or amplifies its effect on folate can push methotrexate levels into a toxic range. Some of these interactions are well-established and dangerous, while others are more theoretical or only matter at certain doses. Understanding which ones actually warrant concern, and which are overhyped, is useful whether you take methotrexate weekly for rheumatoid arthritis or are receiving high-dose infusions for cancer.

Why Methotrexate Is So Interaction-Prone

Methotrexate leaves your body primarily through the kidneys, relying on specific transport proteins in the kidney’s tubules to actively pump it into the urine. Several of these transporters, including OAT1, OAT3, and efflux pumps like BCRP and MRP4, handle methotrexate alongside many other drugs and waste products.¹ When another drug competes for the same transporter, methotrexate can accumulate. Add in the fact that methotrexate also binds to blood proteins like albumin, and you get a second route for trouble: a drug that bumps methotrexate off albumin raises the amount of free, active methotrexate circulating in your blood.² These two mechanisms, renal competition and protein displacement, explain the majority of methotrexate’s drug interactions.

NSAIDs and Methotrexate

This is probably the interaction people worry about the most, because ibuprofen, naproxen, and other NSAIDs are so commonly used alongside methotrexate for inflammatory conditions. The concern dates back decades and has a solid theoretical basis: NSAIDs can reduce blood flow to the kidneys and compete with methotrexate for tubular secretion, potentially slowing its clearance.³ Early case reports of severe toxicity cemented this interaction in prescribing guidelines.

The reality for low-dose methotrexate, though, is more reassuring than the warnings suggest. A recent review evaluating the evidence across multiple pharmacokinetic studies found that NSAIDs have minimal impact on methotrexate levels at low doses, with only minor changes in clearance observed in two out of ten studies examined.⁴ Most of the alarming case reports involved high-dose methotrexate used in cancer treatment, where the stakes are inherently different.⁵ That said, if you have any degree of kidney impairment, the picture changes. Reduced kidney function removes the safety margin, and adding an NSAID on top can be the nudge that tips methotrexate levels higher than expected.

Trimethoprim-Sulfamethoxazole, the Antibiotic to Watch

If there is one drug combination that deserves a genuine red flag with methotrexate, it is trimethoprim-sulfamethoxazole (often sold as Bactrim or Septra). This common antibiotic hits methotrexate from multiple directions at once: it antagonizes folate through its own mechanism, it competes for the same kidney transporters, and it displaces methotrexate from albumin. One study found that concurrent use increased free methotrexate concentrations in the blood by roughly 60%.⁶ Case reports of fatal pancytopenia, where all blood cell lines crash, have been documented. The synergistic folate blockade is the key problem: methotrexate inhibits one enzyme in the folate pathway, and trimethoprim inhibits another, so the two together can shut down folate metabolism almost completely. Most prescribers consider this combination contraindicated, or at minimum something to avoid unless absolutely necessary with close monitoring.

Proton Pump Inhibitors

Omeprazole, esomeprazole, pantoprazole, and their relatives are used so widely for acid reflux that this interaction catches many people off guard. Evidence suggests that PPIs can decrease methotrexate clearance, leading to elevated blood levels of both methotrexate and its metabolite hydroxymethotrexate.⁷ The mechanism is thought to involve inhibition of the same renal transport pumps that methotrexate depends on for excretion. Most of the strong evidence comes from high-dose methotrexate settings, where delayed clearance is carefully tracked. For weekly low-dose methotrexate, the clinical significance is less clear, but some clinicians will temporarily hold a PPI around the time of a high-dose methotrexate infusion as a precaution.

Penicillins and Other Beta-Lactam Antibiotics

Penicillins, including amoxicillin and piperacillin, compete with methotrexate for renal tubular secretion. An early case report documented a toxic methotrexate reaction in a patient simultaneously receiving penicillin and furosemide, attributed to the combined inhibition of methotrexate’s kidney excretion.⁸ While the risk is generally lower than with trimethoprim-sulfamethoxazole, it is worth mentioning to your prescriber any time you’re put on an antibiotic while taking methotrexate, particularly if your kidney function isn’t at full capacity.

Alcohol

Methotrexate is processed in part by the liver, and long-term use carries a risk of liver fibrosis. Adding alcohol into the mix amplifies that risk. A large cohort study of rheumatoid arthritis patients on methotrexate found that drinking more than 21 units of alcohol per week (roughly 10 to 11 standard U.S. drinks) significantly increased rates of liver enzyme elevations, with an adjusted hazard ratio of about 1.85 compared to lower-consumption groups.⁹ Moderate drinking, in the range of 15 to 21 units per week, showed a possible increase in risk but did not reach the same level of certainty. This does not mean occasional light drinking on methotrexate is necessarily dangerous, but the days of telling patients they must never touch a drop are giving way to more nuanced guidance based on quantity.

Caffeine

This one surprises most people. One of the ways methotrexate reduces inflammation is by promoting the release of adenosine, a molecule that dampens immune activity. Caffeine is a direct adenosine receptor blocker. Animal studies have shown that caffeine markedly reversed methotrexate’s anti-inflammatory effects in a rat arthritis model, as measured by joint swelling, tissue damage, and X-ray analysis.¹⁰ Human data is thinner, but clinical observation supports the possibility. A study examining heavy caffeine intake in rheumatoid arthritis patients noted that caffeine’s role as an adenosine receptor antagonist could blunt the drug’s effectiveness.¹¹

More recent research has identified an additional mechanism: caffeine and the related drug theophylline appear to interfere with a T-cell movement pathway driven by thrombospondin-1, which is also a target of methotrexate’s action.¹² None of this means a morning cup of coffee will ruin your treatment, but if you’re a heavy coffee drinker and your methotrexate seems to have stopped working as well, caffeine intake is worth discussing with your rheumatologist.

Folic Acid Supplementation

Folic acid is the interaction most methotrexate patients actually want: the deliberate kind. Because methotrexate works by blocking an enzyme involved in folate metabolism, it tends to cause side effects related to folate depletion, including mouth sores, nausea, elevated liver enzymes, and drops in blood cell counts. A Cochrane review confirmed that supplementation with folic acid during methotrexate treatment reduces gastrointestinal, liver, and mucous membrane side effects.¹³ Most rheumatologists prescribe daily folic acid (typically 1 mg) or a larger weekly dose taken on a day other than the methotrexate day.

Folinic acid (leucovorin) is a stronger methotrexate antagonist than regular folic acid because it is already in the reduced, metabolically active form and bypasses the very enzyme methotrexate blocks.¹⁴ This makes it the preferred rescue agent in oncology when high-dose methotrexate toxicity occurs, but it also means it can blunt methotrexate’s therapeutic effect more than folic acid does. The timing and form of folate supplementation matter, and the standard advice of avoiding folic acid on the same day as methotrexate exists precisely to preserve the drug’s effectiveness while still protecting you from side effects.

Vaccines

Methotrexate suppresses part of the immune response, which creates two distinct vaccine concerns: live vaccines could theoretically cause infection in an immunosuppressed person, and even non-live vaccines might produce a weaker response. A systematic review found that methotrexate appeared to reduce immune responses to certain vaccines, including varicella and herpes zoster vaccines, though not to MMR or yellow fever revaccination.¹⁵

A practical workaround has emerged from more recent evidence: temporarily withholding methotrexate for one to two weeks after vaccination can improve the immune response without significantly increasing the risk of a disease flare.¹⁶ This strategy gained traction during COVID-19 vaccination campaigns and is now being applied more broadly. Your rheumatologist can advise on whether skipping a dose around vaccination time makes sense for your specific situation.

Leflunomide and Other Immunosuppressants

Combining methotrexate with leflunomide, another disease-modifying drug for rheumatoid arthritis, is common practice but carries genuinely heightened risks. In one study, 17% of patients on the combination developed liver enzyme elevations more than three times the upper limit of normal, a rate higher than either drug alone.¹⁷ The same report estimated the incidence of pancytopenia at roughly 1 in 700 for the combination, compared to about 1 in 4,000 for leflunomide alone. Nine out of twelve cases of leflunomide-associated lung inflammation in one database also involved concurrent methotrexate. Animal studies have reinforced these patterns, showing that the combination produced greater bone marrow suppression and liver fibrosis than either drug in isolation.¹⁸ When rheumatologists do combine these drugs, they typically increase the frequency of blood monitoring.

Herbal Supplements and OTC Products

Several herbal and over-the-counter products create interactions that rarely get flagged. White willow bark, sometimes sold as a “natural aspirin,” contains a salicylate precursor that can increase methotrexate blood levels and toxicity the same way aspirin does. St. John’s wort and dong quai both increase sun sensitivity, and since methotrexate also causes photosensitivity, the combination raises the risk of severe sunburn. Potassium citrate, calcium citrate, and magnesium citrate, often taken for kidney stone prevention, make urine less acidic, which can reduce methotrexate excretion and lower its blood levels.¹⁹

Less commonly discussed herbs like black cumin, white peony root, and licorice have also been examined for interactions with methotrexate, with results going in both directions, some reducing toxicity and others amplifying it.²⁰ The evidence base for herbal interactions is generally weaker than for pharmaceuticals, which is itself a reason for caution: the absence of well-documented interactions doesn’t mean they don’t exist. If you take herbal supplements regularly, bring the full list to your prescriber.

Kidney Function, Aging, and Diuretics

Because the kidneys do the heavy lifting in clearing methotrexate, anything that impairs kidney function amplifies every other interaction on this list. Older adults are at particular risk because kidney function declines naturally with age, often without obvious symptoms. A study of elderly patients who developed severe methotrexate toxicity found that most cases were linked to an acute or gradual decline in kidney function, with some patients found to be in advanced stages of kidney disease at the time of admission.²¹ Diuretics like furosemide can worsen the situation by reducing kidney blood flow and competing for renal transport. Even something as ordinary as a bout of stomach flu, causing dehydration, can temporarily impair clearance enough to trigger toxicity. Regular monitoring of kidney function is essential for anyone on long-term methotrexate, and your dose may need to be adjusted downward as kidney function changes over time.

High-Dose Methotrexate Rescue

In oncology settings where methotrexate is given at doses hundreds of times higher than weekly rheumatology doses, delayed clearance is a medical emergency. Leucovorin rescue, where folinic acid is given on a schedule after the methotrexate infusion, is the standard safety net. But when kidneys fail to clear the drug adequately, leucovorin alone may not be enough. Glucarpidase is a rescue enzyme approved by the FDA that rapidly breaks down circulating methotrexate into inactive fragments, reducing blood levels by more than 95% within 15 minutes.²² Expert consensus guidelines recommend its use when methotrexate levels remain dangerously high at specific time points after infusion, particularly if kidney injury is present. Because glucarpidase cannot enter cells, leucovorin must still be continued afterward to protect cells that have already absorbed the drug.²³

Genetic Variation in How the Body Handles Methotrexate

Not everyone processes methotrexate the same way, and some of that variation is genetic. Research into pharmacogenomics has identified gene variants in the transporter proteins and folate pathway enzymes that influence both how well methotrexate works and how toxic it becomes. A review of the evidence found that variants in the SLCO1B1 gene (which encodes a liver transporter) and the ARID5B gene are the most clearly linked to differences in methotrexate blood levels and toxicity risk in leukemia patients receiving high-dose treatment.²⁴ Variants in genes like MTHFR, which affects folate metabolism, and in various ABC transporter genes have also been studied, though with less consistent results across populations.²⁵ Routine pharmacogenomic testing before methotrexate therapy is not standard practice yet, but it is moving in that direction, particularly in pediatric oncology.

The Gut Microbiome Connection

An emerging and still somewhat speculative area is the relationship between methotrexate and the bacteria living in your gut. In animal studies, certain gut bacteria from the Prevotellaceae family produce an enzyme that converts methotrexate into an inactive metabolite. The abundance of these bacteria correlated with how much of the inactive form appeared in stool samples.²⁶ The relationship goes both ways: high-dose methotrexate itself shifted the gut microbial community, increasing certain bacterial groups while decreasing others. If this pans out in human research, your gut bacteria composition might someday factor into methotrexate dosing decisions. For now, the practical implication is that anything dramatically altering your gut flora, such as a course of broad-spectrum antibiotics, could theoretically change how you handle methotrexate, though this remains unproven in clinical settings.

Pregnancy and Methotrexate

Methotrexate is a known teratogen, meaning it can cause severe birth defects, and this holds true even at the low weekly doses used for rheumatoid arthritis. A case report documented a characteristic pattern of birth defects, known as methotrexate embryopathy, in a pregnancy exposed to the standard low once-weekly dose, the first such case described at that dosing schedule.²⁷ Guidelines recommend stopping methotrexate well before conception, typically at least three months for both women and men, to allow the drug to fully clear. This is one area where there is no nuance or dose-dependent gray zone: any pregnancy exposure is considered a serious risk, and reliable contraception during treatment is essential.

1
PubMed Central. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters ↩︎
2
PubMed Central. Simultaneous Binding of Folic Acid and Methotrexate to Human Serum Albumin: Insights into the Structural Changes of Protein and the Location and Competitive Displacement of Drugs ↩︎
3
PubMed. Methotrexate and nonsteroidal antiinflammatory drug interactions ↩︎
4
PubMed. Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs ↩︎
5
PubMed. Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors ↩︎
6
PubMed Central. A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole ↩︎
7
PubMed Central. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors ↩︎
8
JAMA Dermatology. Toxic Reaction to Methotrexate in a Patient Receiving Penicillin and Furosemide: A Possible Interaction ↩︎
9
PubMed Central. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate ↩︎
10
Arthritis & Rheumatism. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine ↩︎
11
Annals of the Rheumatic Diseases. FRI0034 Does heavy caffeine ingestion affect the efficacy of methotrexate ↩︎
12
PubMed. Methotrexate and its therapeutic antagonists caffeine and theophylline, target a motogenic T-cell mechanism driven by thrombospondin-1 (TSP-1) ↩︎
13
PubMed Central. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis ↩︎
14
Australian Prescriber. Folate for therapy ↩︎
15
PubMed. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation ↩︎
16
PubMed. Vaccinating patients with autoimmune diseases ↩︎
17
Prescriber Update. Leflunomide – Update on Serious Toxicity ↩︎
18
PubMed. Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis ↩︎
19
EBSCO CAM Review. Methotrexate ↩︎
20
Alternative and Complementary Therapies. Herbs and Immunosuppressive Drugs: Corticosteroids, Methotrexate, and Others ↩︎
21
RMD Open. Severe methotrexate toxicity in elderly patients under diuretics ↩︎
22
PubMed Central. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance ↩︎
23
The Oncologist. Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance ↩︎
24
PubMed Central. Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia ↩︎
25
Egyptian Journal of Medical Human Genetics. Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism ↩︎
26
PubMed Central. A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats ↩︎
27
Elsevier / PubMed Central. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy ↩︎